CHICAGO — In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting have shown.1

The median overall survival observed with sorafenib of approximately 10 months “is consistent with previous reports,” said Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, on behalf of the Intergroup and Alliance CALGB 80802 investigators.

Continue Reading